What Grace Therapeutics’ STRIVE-ON data may change in neurocritical care
Grace Therapeutics’ GTx-104 heads to AAN 2026 just before FDA decision day. Find out what this could change in neurocritical care.
Pharma & Biotech
Pharma & Biotech
Could Hinge Bio, Inc. unlock a new class of lupus B-cell depletion therapies?
Hinge Bio, Inc. doses first subjects in HB2198 Phase 1 trial. Discover what this could mean for lupus treatment and next-generation immune reset therapies.
Pharma & Biotech
What Actuate Therapeutics’ Phase 2 survival data means for pancreatic oncology
Read how Actuate Therapeutics’ elraglusib survival data could reshape first-line pancreatic cancer treatment and what regulators may watch next.
Pharma & Biotech
How Cellectar Biosciences, Inc. is positioning CLR 125 for a differentiated TNBC treatment thesis
Cellectar Biosciences, Inc. begins CLR 125 Phase 1b in refractory TNBC. Read what this could mean for precision radioconjugate oncology.
Pharma & Biotech
How the Lixte Biotechnology Holdings and dostarlimab study could influence future ovarian cancer trial design
Lixte Biotechnology’s LB-100 ovarian cancer data may signal a new immunotherapy pathway. Read what this could change for the sector.
Pharma & Biotech
Could Septerna open a new chapter in disease-modifying hypoparathyroidism treatment?
Could Septerna’s SEP-479 change hypoparathyroidism care? Read how this Phase 1 launch may reshape rare endocrine treatment pathways.
Pharma & Biotech
Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?
Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.
Pharma & Biotech
How Veld Pharmaceuticals and Chiesi Farmaceutici are expanding rare disease therapy access in Africa
Chiesi Farmaceutici and Veld Pharmaceuticals expand rare disease therapy access across Africa. Discover what this means for market access and regulation.
Pharma & Biotech
Can Vedanta Biosciences turn microbiome therapeutics into a real prevention strategy for recurrent CDI and resistant infections?
Vedanta Biosciences unveiled VE303 and VE707 data at ESCMID 2026. Read why the microbiome strategy matters for CDI and resistant infections.
Pharma & Biotech
Does Verastem Oncology’s updated RAMP 201 dataset change the outlook for low-grade serous ovarian cancer treatment?
Verastem Oncology’s two-year ovarian cancer data strengthen the case for avutometinib plus defactinib. Read what this means next.